Study in COvid-19 Patients With iveRmectin (CORVETTE-01)
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
Treatment of mild COVID-19 is basically performed at an outpatient clinic, then when the
symptom and clinical findings exacerbate to a moderate level, patients are admitted. There is
no standard treatment for mild cases. This study will investigate whether ivermectin
administration suppresses the replication of SARS-CoV-2 in mild to moderate COVID-19 by
investigating the negative rate of SARS-CoV-2 PCR by a randomized controlled trial. Subjects
are assigned to two groups, the placebo group, and the ivermectin group. The target number of
each treatment arm is 120, a total of 240 cases. A single oral administration of 200 ㎍/kg of
ivermectin or an ivermectin-free placebo will be administered on an empty stomach. Time to
negativization of SARS-CoV-2 PCR as the primary endpoint with additional efficacy and safety
of the process will be investigated.